NVO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk wins EU backing for oral Wegovy, expanding weight-loss options
Novo Nordisk’s oral semaglutide tablet received a positive opinion from the European Medicines Agency’s CHMP on June 5, 2026. The recommendation includes four...
🟢 Novo Nordisk A/S is trading 5.3% up today on sector enthusiasm and new clinical trial supply agreement
Novo Nordisk A/S is trading 5.3% up at $44.23 today, buoyed by positive sentiment in the weight-loss drug sector and a new company-specific development. •...
🟢 Novo Nordisk A/S is trading 4.5% up today on UAE launch of oral Wegovy pill
Novo Nordisk A/S is trading 4.5% up today at $43.88 following the launch of its oral Wegovy pill in the UAE, marking the first market outside the U.S. for this...
Novo Nordisk launches Wegovy pill in UAE, first market outside U.S.
Novo Nordisk launched the oral Wegovy pill in the United Arab Emirates on June 3, 2026. The UAE is the first country outside the United States to offer the...
🔴 Novo Nordisk A/S is trading 3% down today on renewed obesity-drug competition concerns
Novo Nordisk A/S is trading 3% down today at $44.20 as investors reassess long-term competitive dynamics in the obesity-drug market. • The decline follows...
Novo Nordisk to Lower Ozempic Cost for Uninsured Canadians
Novo Nordisk Canada launches a new Ozempic® savings program on May 29, 2026. The initiative targets patients lacking public or private drug coverage. The...
Novo Nordisk, Eli Lilly win French reimbursement, marking an EU first
France will begin reimbursing Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro starting mid-June 2026. This decision makes France the first European Union nation...
Novo Nordisk wins EU backing for Wegovy pill, outpacing Eli Lilly
The European Medicines Agency’s CHMP recommended marketing authorization for two Novo Nordisk obesity treatments. These include the Wegovy pill (oral...
Novo Nordisk's Higher-Dose Wegovy Pen Recommended for EU Approval
An EMA expert panel recommended approving Novo Nordisk's Wegovy 7.2 mg single-dose pen for adults with obesity. The new pen offers a weekly injection. The...
Novo Nordisk Wins EU Backing for Wegovy Pill, Nearing First Oral Treatment
Novo Nordisk received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its oral semaglutide...
Novo Nordisk Reclaims Market Share, Oral Wegovy Prices Rival Compounded Drugs
U.S. doctors report a notable shift as patients transition from compounded GLP-1 medications to branded oral options. Patients are moving to Novo Nordisk’s...
Novo Nordisk Slumps, Facing Canadian Generics and Record Eli Lilly Data
Hims & Hers launched generic semaglutide on its Canadian telehealth platform on May 21, 2026. The company is using a version produced by Apotex following the...
Novo Nordisk loses Ozempic monopoly, generic rivals launch in Canada
Generic versions of semaglutide begin arriving in Canadian pharmacies this week. Health Canada approved these drugs from manufacturers Apotex and Dr. Reddy’s...
Novo Nordisk to Unveil Semaglutide MASH Data, Targeting 250 Million Patients
Novo Nordisk will present new data on semaglutide for metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the...
Novo Nordisk launches Wegovy pill globally, countering US pricing and generic rivals
Novo Nordisk plans to launch its oral weight-loss drug, Wegovy, in international markets later this year pending regulatory approvals. The company’s executive...
Novo Nordisk A/S Q1 2026 Earnings Preview: What Analysts Expect on May 06, 2026
Consensus forecasts peg Q1 revenue at $11.84 billion and EPS at $0.87, as the stock trades at $164.20 against an average analyst target of $188.50. Investors...